胰腺神经内分泌肿瘤大小:显微镜、CT、MRI与大体病理测量的一致性研究
本研究纳入64例病理确诊的胰腺神经内分泌肿瘤患者,比较显微镜、CT、MRI与病理大体标本测量的肿瘤大小一致性及对T分期的影响。结果显示病理与影像测量间一致性良好,但显微镜测量与其他方法一致性差;以大体病理为参考,显微镜、CT、MRI分别有18.75%、23.44%、20.31%患者T分期发生改变。显微镜、CT、MRI测量大小均与大体肿瘤大小显著相关。
要点
- 病理大体与CT/MRI测量肿瘤大小一致性良好,可相互参考。
- 显微镜测量与其他方法一致性差,不宜直接替代大体或影像大小。
- 以大体病理为参考,CT/MRI测量可导致约20%–23%病例T分期改变。
核心结论
- 显微镜、CT和MRI测量的胰腺神经内分泌肿瘤大小均与病理大体肿瘤大小显著相关。
研究设计与样本
- 单中心研究纳入64例病理确诊的胰腺神经内分泌肿瘤患者,于2016年12月至2019年9月期间接受影像检查。
- 肿瘤大小分别通过CT、MRI、病理大体标本分析和显微镜检查测量。
- 采用单因素和多因素logistic回归模型分析MRI与显微镜测量肿瘤大小的关系。
诊断标准与关键数值
- 以病理大体标本分析的T分期为参考,显微镜评估中12/64例(18.75%)T分期改变。
- 以病理大体标本分析的T分期为参考,CT评估中15/64例(23.44%)T分期改变。
- 以病理大体标本分析的T分期为参考,MRI评估中13/64例(20.31%)T分期改变。
- 全调整模型中,显微镜大小(β=1.05,95%CI 0.98-1.12,P<.001)、CT大小(β=0.90,95%CI 0.78-1.02,P<.001)、MRI大小(β=0.92,95%CI 0.81-1.04,P<.001)与大体肿瘤大小显著相关。
临床应用与阅片要点
- 日常阅片报告胰腺神经内分泌肿瘤大小时,可参考CT或MRI测量值评估大体肿瘤大小。
- 需注意CT或MRI测量可能导致约20%–23%病例T分期与大体病理不一致。
- 显微镜测量大小与其他方法一致性差,报告中不宜将显微镜大小等同于影像或大体大小。
局限性
- 单中心研究,样本量64例,结论外推需谨慎。
- 未报告阅片者间一致性及影像设备/序列细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE. The purpose of the present study was to assess the consistency of measurements of pancreatic neuroendocrine tumor (PNET) tumor size obtained using pre-operative imaging, pathologic gross specimen analysis, and microscopic examination of large pathologic sections; evaluate the impact of differences in pathologic and radiologic measurements of size on T categorization; and investigate the exact relationships among tumor size measurements obtained from microscopic analysis, CT, MRI, and pathologic gross specimen analysis. MATERIALS AND METHODS. We enrolled 64 patients with pathologically confirmed PNETs who underwent radiologic examination between December 2016 and September 2019. Tumor sizes were measured by CT, MRI, pathologic gross specimen analysis, and microscopic examination. The relationship between the tumor sizes calculated by MRI and microscopy was analyzed using univariate and multivariate logistic regression models. RESULTS. The measurements of tumor sizes calculated by pathologic and radiologic assessments and CT and MRI assessments showed good concordance, but measurements calculated by microscopic analysis and other methods showed poor concordance. When T categories from pathologic gross specimen analysis were considered the reference, alterations in T category were found in the microscopic assessments of 12 of 64 patients (18.75%), CT assessments of 15 of 64 patients (23.44%), and MRI assessments of 13 of 64 patients (20.31%). In the fully adjusted model, microscopic size (β, 1.05; 95% CI, 0.98-1.12; p < .001), CT size (β, 0.90; 95% CI, 0.78-1.02; p < .001), and MRI size (β, 0.92; 95% CI, 0.81-1.04; p < .001) were significantly correlated with gross tumor size. CONCLUSION. Tumor sizes measured by microscopy, CT, and MRI were significantly associated with the gross size of PNETs. This finding provides physicians with new tools for rapid identification of gross tumor size.
引用
- Bian Y, Li J, Jiang H, et al. Tumor Size on Microscopy, CT, and MRI Assessments Versus Pathologic Gross Specimen Analysis of Pancreatic Neuroendocrine Tumors. AJR Am J Roentgenol. 2021. PMID: 33978449. doi:10.2214/AJR.20.23413
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。